1932
0
  1. Home
  2. A-Z Publications
  3. Annual Review of Medicine
  4. Volume 67, 2016
  5. Article

Annual Review of Medicine

Volume 67, 2016

New Vaccines for the World's Poorest People

Abstract

The 2000 Millennium Development Goals helped stimulate the development of life-saving childhood vaccines for pneumococcal and rotavirus infections while greatly expanding coverage of existing vaccines. However, there remains an urgent need to develop new vaccines for HIV/AIDS, malaria, and tuberculosis, as well as for respiratory syncytial virus and those chronic and debilitating (mostly parasitic) infections known as neglected tropical diseases (NTDs). The NTDs represent the most common diseases of people living in extreme poverty and are the subject of this review. The development of NTD vaccines, including those for hookworm infection, schistosomiasis, leishmaniasis, and Chagas disease, is being led by nonprofit product development partnerships (PDPs) working in consortia of academic and industrial partners, including vaccine manufacturers in developing countries. NTD vaccines face unique challenges with respect to their product development and manufacture, as well as their preclinical and clinical testing. We emphasize global efforts to accelerate the development of NTD vaccines and some of the hurdles to ensuring their availability to the world's poorest people.

Keyword(s): diseases of poverty, global access, neglected tropical diseases, parasites, product development partnerships
Loading

Article metrics loading...

/content/journals/10.1146/annurev-med-051214-024241
2016-01-14
2024-04-24
Loading full text...

Full text loading...

/deliver/fulltext/med/67/1/annurev-med-051214-024241.html?itemId=/content/journals/10.1146/annurev-med-051214-024241&mimeType=html&fmt=ahah

Literature Cited

  1. Sachs J. 1.  2001. Macroeconomics and Health: Investing in Health for Economic Development Geneva: World Health Organ.
  2. 2. GBD Mortality and Causes of Death Collab 2015. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385:117–71 [Google Scholar]
  3. 3. United Nations Development Programme 2014. The Millennium Development Goals Report http://www.undp.org/content/dam/undp/library/MDG/english/UNDP_MDGReport_EN_2014Final1.pdf
  4. Hotez PJ, Herricks J. 4.  2015. What kills little kids?. PLOS Blog Feb. 24. http://blogs.plos.org/speakingofmedicine/2015/02/24/kills-little-kids/
  5. 5. WHO 2015. Global vaccine action plan 2011–2020 http://www.who.int/immunization/global_vaccine_action_plan/en/
  6. 6. WHO 2012. Global vaccine action plan http://www.who.int/immunization/global_vaccine_action_plan/GVAP_Strategic_Objective_1-6.pdf
  7. Murray CJ, Ortblad KF, Guinovart C. 7.  et al. 2014. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 384:1005–70 [Google Scholar]
  8. Beaumier CM, Gillespie PM, Hotez PJ, Bottazzi ME. 8.  2013. New vaccines for neglected parasitic diseases and dengue. Transl. Res. J. Lab. Clin. Med. 162:144–55 [Google Scholar]
  9. Breitstein J, Spigelman M. 9.  2013. The role of product development partnerships in advancing the development of drugs for unmet needs. Clin. Pharmacol. Ther. 93:468–70 [Google Scholar]
  10. Pratt B, Loff B. 10.  2013. Linking research to global health equity: the contribution of product development partnerships to access to medicines and research capacity building. Am. J. Public Health 103:1968–78 [Google Scholar]
  11. 11. Deutsche Stiftung Weltbevölkerung (DSW) 2014. A healthier world: tackling neglected diseases http://3kck0t38mmqdnrjfp23kzm9tz0.wpengine.netdna-cdn.com/wp-content/uploads/2014/06/DSW-report.pdf
  12. Delany I, Rappuoli R, De Gregorio E. 12.  2014. Vaccines for the 21st century. EMBO Mol. Med. 6:708–20 [Google Scholar]
  13. Agnandji ST, Lell B, Fernandes JF. 13.  RTS,S Clinical Trials Partnership et al. 2012. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N. Engl. J. Med. 367:2284–95 [Google Scholar]
  14. 14.  RTS,S Clinical Trials Partnership 2014. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med. 11:e1001685 [Google Scholar]
  15. Haynes BF, Moody MA, Alam M. 15.  et al. 2014. Progress in HIV-1 vaccine development. J. Allergy Clin. Immunol. 134:3–10 [Google Scholar]
  16. O'Ryan M, Vidal R, Del Canto F. 16.  et al. 2015. Vaccines for viral and bacterial pathogens causing acute gastroenteritis. Part I: Overview, vaccines for enteric viruses and Vibrio cholerae. Hum. Vaccines Immunotherapeut. 11:584–600 [Google Scholar]
  17. Ivers LC, Hilaire IJ, Teng JE. 17.  et al. 2015. Effectiveness of reactive oral cholera vaccination in rural Haiti: a case-control study and bias-indicator analysis. Lancet Global Health 3:e162–68 [Google Scholar]
  18. Chen WH, Greenberg RN, Pasetti MF. 18.  et al. 2014. Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR, prepared from new master and working cell banks. Clin. Vaccine Immunol. 21:66–73 [Google Scholar]
  19. Guvenel AK, Chiu C, Openshaw PJ. 19.  2014. Current concepts and progress in RSV vaccine development. Expert Rev. Vaccines 13:333–44 [Google Scholar]
  20. Tameris MD, Hatherill M, Landry BS. 20.  et al. 2013. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 381:1021–28 [Google Scholar]
  21. Kagina BM, Tameris MD, Geldenhuys H. 21.  et al. 2014. The novel tuberculosis vaccine, AERAS-402, is safe in healthy infants previously vaccinated with BCG, and induces dose-dependent CD4 and CD8T cell responses. Vaccine 32:5908–17 [Google Scholar]
  22. Molyneux DH, Hotez PJ, Fenwick A. 22.  2005. “Rapid-impact interventions”: how a policy of integrated control for Africa's neglected tropical diseases could benefit the poor. PLoS Med. 2:e336 [Google Scholar]
  23. Hotez PJ. 23.  2013. Forgotten People, Forgotten Diseases: The Neglected Tropical Diseases and Their Impact on Global Health and Development Washington, DC: ASM Press
  24. 24. WHO 2015. The 17 neglected tropical diseases http://www.who.int/neglected_diseases/diseases/summary/en/
  25. Hotez PJ, Alvarado M, Basanez MG. 25.  et al. 2014. The global burden of disease study 2010: interpretation and implications for the neglected tropical diseases. PLoS Neglected Trop. Dis. 8:e2865 [Google Scholar]
  26. Hotez PJ, Ferris MT. 26.  2006. The antipoverty vaccines. Vaccine 24:5787–99 [Google Scholar]
  27. Hotez P, Whitham M. 27.  2014. Helminth infections: a new global women's health agenda. Obstet. Gynecol. 123:155–60 [Google Scholar]
  28. Hotez P. 28.  2011. A handful of “antipoverty” vaccines exist for neglected diseases, but the world's poorest billion people need more. Health Aff. 30:1080–87 [Google Scholar]
  29. 29. WHO 2014. Product Development for Vaccines Advisory Committee (established April 2014) http://www.who.int/immunization/research/committees/pdvac/en/ [Google Scholar]
  30. Hotez PJ, Pecoul B, Rijal S. 30.  et al. 2015. Eliminating the neglected tropical diseases: translational science and new technologies. PLoS Neglected Trop. Dis. In press
  31. Bethony JM, Cole RN, Guo X. 31.  et al. 2011. Vaccines to combat the neglected tropical diseases. Immunol. Rev. 239:237–70 [Google Scholar]
  32. Bottazzi ME, Brown AS. 32.  2008. Model for product development of vaccines against neglected tropical diseases: a vaccine against human hookworm. Expert Rev. Vaccines 7:1481–92 [Google Scholar]
  33. Bottazzi ME, Miles AP, Diemert D, Hotez PJ. 33.  2006. An ounce of prevention on a budget: a nonprofit approach to developing vaccines against neglected diseases. Expert Rev. Vaccines 5:189–98 [Google Scholar]
  34. Serruto D, Bottomley MJ, Ram S. 34.  et al. 2012. The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine 30:Suppl. 2B87–97 [Google Scholar]
  35. Seib KL, Zhao X, Rappuoli R. 35.  2012. Developing vaccines in the era of genomics: a decade of reverse vaccinology. Clin. Microbiol. Infect. 18:Suppl. 5109–16 [Google Scholar]
  36. Bethony JM, Periago MV, Jariwala A. 36.  2012. Barefoot thru' the Valley of Darkness: preclinical development of the human hookworm vaccine. Parasitic Helminths: Targets, Screens, Drugs and Vaccines CR Caffrey 343–56 Weinheim, Ger: Wiley-VCH [Google Scholar]
  37. Giersing BK, Dubovsky F, Saul A. 37.  et al. 2006. Potency assay design for adjuvanted recombinant proteins as malaria vaccines. Vaccine 24:4264–70 [Google Scholar]
  38. Seid CA, Curti E, Jones RM. 38.  et al. 2015. Expression, purification, and characterization of the Necator americanus aspartic protease-1 (Na-APR-1 (M74)) antigen, a component of the bivalent human hookworm vaccine. Hum. Vaccines Immunotherapeut. 11:1474–88 [Google Scholar]
  39. Goud GN, Deumic V, Gupta R. 39.  et al. 2012. Expression, purification, and molecular analysis of the Necator americanus glutathione S-transferase 1 (Na-GST-1): a production process developed for a lead candidate recombinant hookworm vaccine antigen. Protein Expr. Purif. 83:145–51 [Google Scholar]
  40. Curti E, Kwityn C, Zhan B. 40.  et al. 2013. Expression at a 20L scale and purification of the extracellular domain of the Schistosoma mansoni TSP-2 recombinant protein: a vaccine candidate for human intestinal schistosomiasis. Hum. Vaccines Immunotherapeut. 9:2342–50 [Google Scholar]
  41. Legrand N, Ploss A, Balling R. 41.  et al. 2009. Humanized mice for modeling human infectious disease: challenges, progress, and outlook. Cell Host Microbe 6:5–9 [Google Scholar]
  42. Siu E, Ploss A. 42.  2015. Modeling malaria in humanized mice: opportunities and challenges. Ann. N.Y. Acad. Sci. 1342:29–36 [Google Scholar]
  43. Kaushansky A, Mikolajczak SA, Vignali M, Kappe SH. 43.  2014. Of men in mice: the success and promise of humanized mouse models for human malaria parasite infections. Cell Microbiol. 16:602–11 [Google Scholar]
  44. Diemert DJ, Pinto AG, Freire J. 44.  et al. 2012. Generalized urticaria induced by the Na-ASP-2 hookworm vaccine: implications for the development of vaccines against helminths. J. Allergy Clin. Immunol. 130:169–76 [Google Scholar]
  45. Hotez PJ, Bethony JM, Diemert DJ. 45.  et al. 2010. Developing vaccines to combat hookworm infection and intestinal schistosomiasis. Nat. Rev. Microbiol. 8:814–26 [Google Scholar]
  46. Alexander N, Cundill B, Sabatelli L. 46.  et al. 2011. Selection and quantification of infection endpoints for trials of vaccines against intestinal helminths. Vaccine 29:3686–94 [Google Scholar]
  47. Spring M, Polhemus M, Ockenhouse C. 47.  2014. Controlled human malaria infection. J. Infect. Dis. 209:Suppl. 2S40–45 [Google Scholar]
  48. 48. ClinicalTrials.gov 2014. Experimental infection of hookworm-naïve adults with dermally-applied infectious Necator americanus hookworm larvae https://clinicaltrials.gov/ct2/show/NCT01940757 [Google Scholar]
  49. Bottazzi ME. 49.  2014. Vaccines against neglected tropical diseases: promising interventions to rescue the poorest populations in the Americas. Immunotherapy 6:117–19 [Google Scholar]
  50. Mgone CS, Salami W. 50.  2009. EDCTP: a genuine north-south partnership. Trop. Med. Int. Health 14:1327–28 [Google Scholar]
  51. Matee MI, Manyando C, Ndumbe PM. 51.  et al. 2009. European and Developing Countries Clinical Trials Partnership (EDCTP): the path towards a true partnership. BMC Public Health 9:249 [Google Scholar]
  52. Zumla A, Makanga M, Nyirenda T. 52.  et al. 2015. Genesis of EDCTP2. Lancet Infect. Dis. 15:11–13 [Google Scholar]
  53. Hotez PJ. 53.  2013. NTDs V.2.0: “blue marble health”—neglected tropical disease control and elimination in a shifting health policy landscape. PLoS Neglected Trop. Dis. 7:e2570 [Google Scholar]
  54. Wade K. 54.  2013. Confronting neglected tropical diseases: Will highly endemic countries buy in?. D Blog Dec. 20. http://dalberg.com/blog/?p=2372
  55. 55. GAVI 2015. Pneumococcal AMC http://www.gavi.org/funding/pneumococcal-amc/
  56. Ridley DB, Sanchez AC. 56.  2010. Introduction of European priority review vouchers to encourage development of new medicines for neglected diseases. Lancet 376:922–27 [Google Scholar]
  57. Ridley DB, Grabowski HG, Moe JL. 57.  2006. Developing drugs for developing countries. Health Aff. 25:313–24 [Google Scholar]
  58. 58. Food and Drug Administration (FDA) 2008. Guidance for industry: tropical disease priority review vouchers. http://www.fda.gov/downloads/Drugs/Guidances/UCM080599.pdf
  59. Gaffney A, Mezher M. 59.  2015. Regulatory explainer: everything you need to know about FDA's priority review vouchers. Regulatory Focus July 2
  60. Stefanakis R, Robertson AS, Ponder EL, Moree M. 60.  2012. Analysis of neglected tropical disease drug and vaccine development pipelines to predict issuance of FDA priority review vouchers over the next decade. PLoS Neglected Trop. Dis. 6:e1803 [Google Scholar]
  61. Slingsby BT, Kurokawa K. 61.  2013. The Global Health Innovative Technology (GHIT) Fund: financing medical innovations for neglected populations. Lancet Global Health 1:e184–85 [Google Scholar]
  62. Moran M, Guzman J, Ropars AL, Illmer A. 62.  2010. The role of Product Development Partnerships in research and development for neglected diseases. Int. Health 2:114–22 [Google Scholar]
  63. 63. Global Health Investment Fund (GHIF) 2014. GHIF leads US$7.5m investment into EuBiologics http://www.lhgp.com/ghif-leads-us7-5m-investment-into-eubiologics/
  64. 64. ClinicalTrials.gov 2015. Safety and immunogenicity study of Na-GST-1 with or without CpG https://clinicaltrials.gov/ct2/show/NCT02143518
  65. 65. ClinicalTrials.gov 2015. Safety and immunogenicity of the Na-APR-1 hookworm vaccine in healthy adults https://clinicaltrials.gov/ct2/show/NCT01717950
  66. 66. ClinicalTrials.gov 2015. Safety and immunogenicity of co-administered hookworm vaccine candidates Na-GST-1 and Na-APR-1 in Gabonese adults https://clinicaltrials.gov/ct2/show/NCT02126462
  67. 67. ClinicalTrials.gov 2015. Study of Na-APR-1 (M74)/Alhydrogel® co-administered with Na-GST-1/Alhydrogel in Brazilian adults https://clinicaltrials.gov/ct2/show/NCT02476773 [Google Scholar]
  68. 68. ClinicalTrials.gov 2011. Safety and immunogenicity of a human hookworm candidate vaccine with different doses of a novel adjuvant https://clinicaltrials.gov/ct2/show/NCT01385189
  69. 69. ClinicalTrials.gov 2012. Efficacy of vaccine Sh28GST in association with praziquantel (PZQ) for prevention of clinical recurrences of Schistosoma haematobium pathology (Bilhvax) https://clinicaltrials.gov/ct2/show/NCT00870649 [Google Scholar]
  70. 70. ClinicalTrials.gov 2015. A Phase I study of the safety, reactogenicity, and immunogenicity of Sm-TSP-2/Alhydrogel® with or without GLA-AF for intestinal schistosomiasis in healthy adults https://clinicaltrials.gov/ct2/show/NCT02337855
  71. 71. ClinicalTrials.gov 2015. Study to evaluate the safety of the vaccine prepared sm14 against schistosomiasis https://clinicaltrials.gov/ct2/show/NCT01154049
  72. 72. ClinicalTrials.gov 2014. Phase 1 LEISH-F3 + SLA-SE vaccine trial in healthy adult volunteers https://clinicaltrials.gov/ct2/show/NCT02071758
  73. 73. ClinicalTrials.gov 2011. Study of a novel tetravalent dengue vaccine in healthy children aged 2 to 14 years in Asia https://clinicaltrials.gov/ct2/show/NCT01373281
  74. 74. ClinicalTrials.gov 2011. Study of a novel tetravalent dengue vaccine in healthy children and adolescents aged 9 to 16 years in Latin America. https://clinicaltrials.gov/ct2/show/NCT01374516
  75. 75. ClinicalTrials.gov 2009. Study of Sanofi Pasteur's CYD dengue vaccine in healthy subjects in Singapore https://clinicaltrials.gov/ct2/show/NCT00880893
  76. 76. ClinicalTrials.gov 2012. Phase II trial to evaluate safety and immunogenicity of a dengue 1,2,3,4 (attenuated) vaccine https://clinicaltrials.gov/ct2/show/NCT01696422 [Google Scholar]
  77. 77. ClinicalTrials.gov 2015. Evaluating the safety and protective efficacy of a single dose of a trivalent live attenuated dengue vaccine to protect against infection with DENV-2 https://clinicaltrials.gov/ct2/show/NCT02433652
  78. 78. ClinicalTrials.gov 2014. TDENV PIV and LAV dengue prime-boost strategy https://clinicaltrials.gov/ct2/show/NCT02239614
  79. 79. ClinicalTrials.gov 2015. Phase III trial to evaluate efficacy and safety of a tetravalent dengue vaccine https://clinicaltrials.gov/ct2/show/NCT02406729
  80. 80. ClinicalTrials.gov 2014. Safety and immunogenicity of different schedules of Takeda's tetravalent dengue vaccine candidate (TDV) in healthy participants https://clinicaltrials.gov/ct2/show/NCT02302066 [Google Scholar]
  81. 81. ClinicalTrials.gov 2015. Safety and immunogenicity with two different serotype 2 potencies of tetravalent dengue vaccine (TDV) in adults in Singapore https://clinicaltrials.gov/ct2/show/NCT02425098 [Google Scholar]
/content/journals/10.1146/annurev-med-051214-024241
Loading
New Vaccines for the World's Poorest People
Annual Review of Medicine 67, 405 (2016); https://doi.org/10.1146/annurev-med-051214-024241
/content/journals/10.1146/annurev-med-051214-024241
/content/journals/10.1146/annurev-med-051214-024241
Loading

Data & Media loading...

  • Article Type: Review Article

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error